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Abstract
Human microvascular pericytes (CD146+/34−/45−/56−) contain multipotent precursors and repair/
regenerate defective tissues, notably skeletal muscle. However, their ability to repair the ischemic
heart remains unknown. We investigated the therapeutic potential of human pericytes, purified
from skeletal muscle, for treating ischemic heart disease and mediating associated repair
mechanisms in mice. Echocardiography revealed that pericyte transplantation attenuated left
ventricular dilatation and significantly improved cardiac contractility, superior to CD56+
myogenic progenitor transplantation, in acutely infarcted mouse hearts. Pericyte treatment
substantially reduced myocardial fibrosis and significantly diminished infiltration of host
inflammatory cells at the infarct site. Hypoxic pericyte-conditioned medium suppressed murine
fibroblast proliferation and inhibited macrophage proliferation in vitro. High expression by
pericytes of immunoregulatory molecules, including IL-6, LIF, COX-2 and HMOX-1, was
sustained under hypoxia, except for MCP-1. Host angiogenesis was significantly increased.
Pericytes supported microvascular structures in vivo and formed capillary-like networks with/
without endothelial cells in three-dimensional co-cultures. Under hypoxia, pericytes dramatically
increased expression of VEGF-A, PDGF-β, TGF-β1 and corresponding receptors while
expression of bFGF, HGF, EGF, and Ang-1 was repressed. The capacity of pericytes to
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differentiate into and/or fuse with cardiac cells was revealed by GFP-labeling, though to a minor
extent. In conclusion, intramyocardial transplantation of purified human pericytes promotes
functional and structural recovery, attributable to multiple mechanisms involving paracrine effects
and cellular interactions.
Keywords
pericytes; angiogenesis; immunomodulation; myocardial infarction; stem cell therapy
Introduction
Coronary heart disease (CHD) is the leading cause of death in the United States, affecting
16.3 million people and accounting for 1 of every 3 deaths in 2007 [1]. Prolonged
pathological interference with the coronary blood supply, such as atherosclerosis and
thromboemboli, results in ischemic cardiomyopathy and/or myocardial infarction (MI) [2].
MI often leads to heart failure (HF) due to the limited capacity of the human heart to repair/
regenerate its damaged myocardium [2,3]. As an alternative to heart transplantation, stem/
progenitor cell therapy (SCT) is deemed promising for restoration of cardiac function and
prevention of progressive HF [3,4]. In particular, human bone marrow precursor cells,
endothelial progenitor cells, skeletal myoblasts, and endogenous cardiac progenitor cells,
have been intensively investigated with uneven success in pre-clinical and clinical trials [3–
6]. Given the vascular origin of CHD pathology, stem/progenitor cells capable of
reconstituting host vascular networks, in addition to other merits, will be ideal cell sources
for SCT.
Microvascular pericytes (aka mural cells or Rouget cells) that tightly encircle capillaries and
microvessels (arterioles and venules) and regulate microvascular physiology have recently
been shown to contain precursor cells endowed with mesodermal differentiation potential
[7]. Pericytes (CD146+/34−/45−/56−) purified by cell sorting from human skeletal muscle,
adipose, placenta, pancreas and other organs repair and regenerate damaged/defective
tissues [8–12] and represent the CD146-positive developmental origin of the heterogeneous
mesenchymal stem/stromal cells (MSCs) [12–16]. Owing to their wide distribution in the
microvasculature, pericytes are regarded as a promising and attractive source of precursor
cells for regenerative medicine [17–19]. We hypothesize SCT with purified pericytes to be a
suitable approach for the treatment of ischemic heart disease (IHD) [20].
Besides cardiomyogenesis, cardioprotective mechanisms, including anti-fibrosis, anti-
inflammation, and neovascularization, play critical roles in SCT-mediated cardiac repair
following ischemic insults [21–23]. SCT reduces myocardial fibrosis and induces favorable
tissue remodeling in the ischemic heart, which in turn increases myocardial compliance/
strength and prevents the progressive, pathological decline toward HF [24,25]. This anti-
fibrotic feature was attributed in part to increased collagen degradation by matrix
metalloproteinases (MMPs) and inhibition of fibroblast activation, possibly through a
paracrine mechanism [26,27]. Additionally, the immunosuppressive/anti-inflammatory
capacity of MSCs through secretion of immunoregulatory molecules has recently attracted
clinical attention in organ transplantation and immune regulation [28,29]. Whether pericytes
possess similar anti-fibrotic and immunoregulatory capacities within the ischemic
microenvironment remains to be addressed.
To relieve the underlying cause of IHD, SCT-based approaches toward myocardial
revascularization have been extensively pursued [30,31]. Due to their native vascular
localization and secretion of trophic factors that are associated with tissue repair and
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vascular growth/remodeling, pericytes may restore injured vascular networks more
efficiently [18]. Pro-angiogenic signaling molecules released by stem/progenitor cells
stimulate neovascularization in ischemic tissues [31]. Additionally, cell-cell interaction
between vascular mural cells and endothelial cells was lately suggested to play essential
roles in blood vessel remodeling and maturation [32,33]. Whether pericytes mediate
revascularization of the ischemic myocardium through any of these two mechanisms has yet
to be tested
In the present study, we investigated the therapeutic potential of purified human skeletal
muscle pericytes in IHD, using an acute MI (AMI) model in immunodeficient mice.
Transplantation of pericytes not only reversed cardiac dilatation but also improved cardiac
contractility. Major repair mechanisms were investigated, including reduction of fibrosis,
inhibition of chronic inflammation, promotion of angiogenesis, and regeneration of the
myocardium. We further describe putative mediators employed by pericytes. GFP-labeling
was used to track perivascular homing and lineage fate of transplanted pericytes. Our results
demonstrate that the overall benefit of pericyte treatment is collectively attributed to
multiple cardioprotective mechanisms that involve paracrine and direct cell-cell interactions.
Material and Methods
Human Tissue Biopsies and Cell Isolation
In total, 3 independent human skeletal muscle specimens (1 adult and 2 fetal) were used for
cell isolation. The procurement of adult muscle biopsies from the National Disease Research
Interchange was approved by the Institutional Review Board (IRB) at the University of
Pittsburgh. Muscle biopsies (male subject, 57 years old) were preserved in DMEM
containing 1% antibiotics and transported to the laboratory on ice. Human fetal tissues (21
and 23 weeks of gestation) were obtained following voluntary pregnancy interruptions
performed at Magee Womens Hospital, Pittsburgh, in compliance with IRB protocol
0506176. Informed consents for the use of fetal tissues were obtained from all patients. Cells
were mechanically and enzymatically dissociated from muscle biopsies following the
reported protocol [12]. Details are described in supplemental material.
Fluorescence-activated Cell Sorting (FACS) and Flow Cytometry Analysis
FACS and flow cytometry were used to purify microvascular pericytes (CD146+/34−/45−/
56−) and examine cell lineage marker expression respectively, as we previously reported
[12]. Details are documented in supplemental material.
Cell Culture and Cell Labeling
Sorted pericytes were expanded in reported culture conditions [12]. Single donor-derived
human umbilical cord vein endothelial cells (HUVECs, Lonza) were cultured in endothelial
cell growth medium-2 (EGM-2, Lonza). Cultured pericytes were labelled with green
fluorescence protein (GFP) following a published protocol [12], using a lentivirus-based
CMV-driven eGFP-expression vector. For short-term experiments, cells were labelled with
cell membrane dyes, PKH26 (red) and PKH67 (green) (both from Sigma-Aldrich), and used
immediately without further expansion.
Cell Transplantation in an Acute Myocardial Infarction Model
The Institutional Animal Care and Use Committee at Children’s Hospital of Pittsburgh and
University of Pittsburgh approved the animal usage and surgical procedures
(Protocol#37-04, 55-07, 0901681A-5). A total of 78 male NOD/SCID mice (Jackson
Laboratory) were used. MI induction (by ligation of left anterior descending coronary artery)
and intramyocardial cell injection (3×105 cells/heart) were performed by a blinded surgeon
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as previously reported [34]. Control mice received injections of 30 μl phosphate-buffered
saline (PBS).
Evaluation of Cardiac Function by Echocardiography
Mice were anesthetized with isoflurane and transthoracic echocardiography was performed
by a blinded investigator repeatedly before and after surgery (at 2 and 8 weeks), using a high
resolution ultrasound system (Vevo 770, Visual Sonics), as described previously [34]. Mice
which died prior to 8 weeks post-injection were excluded. Echocardiographic measurements
are listed in supplemental material.
Histological and Immunohistochemical Analyses
At 1, 2, and 8 weeks post-surgery, hearts were harvested and processed as previously
described [34]. Cryosections at 6–8 μm thickness were used for histological and
immunohistochemical analyses following published protocols [34]. Anti-GFP
immunofluorescent staining was performed on 4% paraformaldehyde-fixed sections. Donor
cell engraftment and perivascular homing were quantified on serial sections stained with
anti-GFP antibody (Abcam) and dual-stained with anti-GFP/anti-mouse CD31 (BD
Biosciences) antibodies respectively, using Image J. The engraftment ratio was defined as
the extrapolated total number of engrafted GFP-positive cells to the initial 3×105 cells
injected. Perivascular homing ratio was defined as the extrapolated number of GFP-positive
cells juxtaposing CD31-positive mouse endothelial cells to the extrapolated total number of
engrafted cells. Using Masson’s trichrome staining (San Marcos), fibrotic area fraction and
infarct wall thickness were estimated from 6 randomly selected sections at comparable
infarct levels per heart as previously described [34]. Quantification of host angiogenesis and
chronic inflammation was computed from 6–10 randomly selected images taken from the
designated area in sections stained with anti-mouse CD31 and anti-mouse CD68 (Abcam) at
the mid-infarct level respectively. Experimental details are documented in supplemental
material.
Hypoxia Assay and ELISA
To simulate the lower oxygen tension at the tissue level, physiologically or pathologically,
pericytes were cultured under 2.5% O2 hypoxic conditions (with 5% CO2 and 92.5% N2) as
formerly described [34]. Cells were washed twice before defined, serum-free DMEM
medium was added upon the transition to low O2 conditions. Culture supernatant and cell
lysates were collected 24 hours later. Cells cultured under 21% O2 (normoxia) served as
controls. The secretion of vascular endothelial growth factor (VEGF), angiopoietin-1
(Ang-1), angiopoietin-2 (Ang-2), and transforming growth factor (TGF)-β1 in the culture
supernatant was measured by respective enzyme-linked immunosorbent assay (ELISA) with
human VEGF (Invitrogen), Ang-1, Ang-2, and TGF-β1 (all from R&D Systems) ELISA
Kits.
Real-time Quantitative PCR and Semi-quantitative RT-PCR
Real-time quantitative PCR (rt-qPCR) was performed as previously reported [9]. Total RNA
(N=6) was extracted for cDNA synthesis. The quantitative analyses were performed in the
core facility at the University of Pittsburgh. All data are presented as expression level
normalized to human cyclophilin (in arbitrary fluorescence units). For semi-quantitative RT-
PCR (sqRT-PCR), total RNA (N=3) were extracted using RNeasy plus-mini-kits (Qiagen).
From each sample, 500ng of total RNA were reverse transcribed, followed by PCR. The
intensity of the product bands were calculated using Quantify-One software and normalized
to β-actin. The primer sequences are listed in supplemental table T1 and T2.
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In vitro Vascular Network Formation
Cell culture/co-culture experiments using 2D and 3D Matrigel systems were performed to
observe the capillary-like network formation. For 2D culture, 5×104 pericytes or HUVECs
were seeded onto Matrigel-coated well and incubated for 24 hours. For 3D culture, 25×104
pericytes or HUVECs were re-suspended in EGM-2 medium and mixed with Matrigel in a
3:1 ratio. The Matrigel plug was subsequently incubated for 72 hours. Equal numbers of
dye-labeled pericytes and HUVECs were well mixed in 2D or 3D co-culture for 72 hours to
observe pericyte-HUVEC interactions.
Measurement of Cell Proliferation
Murine RAW264.7 monocyte/macrophage cells (ATCC) or primary murine skeletal
myoblasts, muscle fibroblasts, and cardiac fibroblasts were cultured with normoxic or
hypoxic pericyte-culture conditioned medium, or with serum-free control medium, for 72
hours. Cell proliferation was measured by the absorbance at 490nm after incubation with
CellTiter Proliferation Assay Reagent (Promega) for 3 hours. Experiments were performed
in quadruplicates and repeated 3 times independently.
Statistical Analysis
All measured data are presented as mean ± standard error (SE). Kaplan-Meier survival curve
estimation with log-rank test was performed to compare the animal survival rate between
treatment groups. Statistical differences were analyzed by Student’s t-test (two groups), one-
way ANOVA (multiple groups), or two-way repeated ANOVA (repeated echocardiographic
measurements) with 95% confidence interval. Statistical significance was set at p<0.05.
Student-Newman-Keuls multiple comparison test (or Bonferroni test if specified) was
performed for ANOVA post-hoc analysis. Statistical analyses were performed with
SigmaStat 3.5 (Systat Software) and SPSS19 (IBM) statistics software.
Results
Isolation and Transplantation of Human Pericytes
As reported in our previous studies [12], FACS was used to purify human microvascular
pericytes (CD146+/34−/45−/56−) to homogeneity from skeletal muscle biopsies of three
donors (one adult and two fetal, designated as AP, FP1, and FP2 respectively), by their
differential expression of cell lineage markers, including CD34 (endothelial/stem cells),
CD45 (hematolymphoid cells), CD56 (myogenic cells), and CD146 (pericyte/endothelial
cells) (Supplemental Figure S1). No phenotypical difference between adult and fetal
pericytes was noted, consistent with our previous observations [12]. After in vitro expansion
(25–35 cell doublings) and prior to transplantation, in all three pericyte populations, we have
observed no alteration to their distinctive morphology as well as classic antigenic profile,
including robust expression of CD146, alkaline phosphatase (ALP), and typical MSC
markers: CD44, CD73, CD90, CD105 with the absence of CD34, CD45, and CD56
(Supplemental Figure S2A and S2B). Additionally, cell labeling (in subsequent
experiments) did not alter pericyte phenotype (data not shown). Cells (3.0×105 cells/heart)
resuspended in 30μl PBS were injected into the acutely infarcted myocardium of
immunodeficient mice. The control group received injections of 30μl PBS following the
induction of MI.
Human Pericyte Transplantation Improves Cardiac Function
The survival of animals receiving pericyte treatment or PBS injection was monitored over
the course of 8 weeks (Kaplan-Meier survival curve, log-rank test p=0.529, Figure 1A).
Cardiac function was assessed by echocardiography performed repeatedly before (healthy)
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and at 2 and 8 weeks after surgery (Supplemental Figure S3). Ischemic hearts injected with
either of the three pericyte populations (N=8 per donor) had significantly smaller left
ventricular (LV) chamber size, as measured by LV end-diastolic area (LVEDA, Figure 1B)
and end-systolic area (LVESA, Figure 1C), than the control group (N=8) (all p<0.05),
suggesting the reversal of progressive heart dilatation. Moreover, all pericyte-transplantation
groups displayed significantly better LV contraction, evaluated by LV fraction shortening
(LVFS, Figure 1D), LV fractional area change (LVFAC, Figure 1E), and LV ejection
fraction (LVEF, Figure 1F), than the control group (all p<0.05). Collectively, when
compared to vehicle treatment, pericyte treatment not only resulted in considerably smaller
LV chamber dimension (p<0.001, two-way repeated ANOVA) but also notably improved
LV contractility (p<0.001, two-way repeated ANOVA) for up to 2 months. Dimensional and
functional echocardiographic parameters are documented in Supplemental Table T3. In a
separate experiment, we compared cardiac function of acutely infarcted hearts injected with
either APs or CD56+ myogenic progenitors, sorted from a single adult muscle biopsy. The
echocardiographic results at 2 weeks post-infarction showed that pericyte-treated hearts
(N=6) have significantly better LV function than CD56+ progenitor-treated ones (N=6) in
five parameters examined, including LVEDA (p=0.004), LVESA (p=0.002), LVFS
(p=0.003), LVFAC (p=0.003), and LVEF (p≤0.001) (Supplemental Figure S4).
Transplantation of Pericytes Reduces Cardiac Fibrosis
To understand the influence of pericyte treatment on cardiac fibrosis, we evaluated scar
tissue formation using Masson’s trichrome histological staining. At 2 weeks post-infarction,
pericyte-treated hearts displayed less collagen deposition (stained in blue/purple) at the
ischemic area (Figure 2A). Estimation of the total fibrotic tissue ratio unveiled a 45.3%
reduction of cardiac fibrosis in the pericyte-injected myocardium (N=5, 22.03±1.81%) when
comparing to saline-injected controls (N=5, 40.28±2.15%) (Figure 2B, p≤0.001), suggesting
the anti-fibrotic efficacy of pericytes. Measurement of LV wall thickness at the center of the
infarct indicated no significant difference (p>0.05) between the pericyte group (0.255±0.026
mm) and the PBS group (0.202±0.040 mm), suggesting that pericytes had limited beneficial
effects to reduce transmural infarct thinning following MI (Figure 2C).
Paracrine Anti-fibrotic Effects of Pericytes under Hypoxia
Oxygen tension within tissues, physiologically or pathologically, is considerably lower than
the ambient oxygen concentration in vitro. To elucidate the mechanism involved in pericyte-
mediated reduction of fibrosis, we mimicked, at least in part, the hostile hypoxic
microenvironment that donor cells encounter within the ischemic myocardium by culturing
pericytes under 2.5% oxygen for 24 hours in defined, serum-free medium. Pericytes cultured
under 21% oxygen (normoxia) served as controls. We then performed a cell proliferation
assay using primary murine skeletal muscle and cardiac fibroblasts as well as skeletal
myoblasts cultured with pericyte-conditioned medium (P-CM). Cardiac fibroblast
proliferation was significantly reduced when cultured in hypoxic P-CM, compared to
normoxic P-CM (p=0.019) (Figure 2D). Muscle fibroblast proliferation exhibited the same
inhibitory pattern (p<0.001, hypoxic versus normoxic P-CM) with normoxic P-CM showing
a pro-proliferative effect over control serum-free medium (p<0.05) (Figure 2D). Neither of
the two P-CMs had significant influence over skeletal myoblast proliferation (p=0.76). One-
way ANOVA with Bonferroni multiple comparisons was performed for statistical analysis.
This suggests a paracrine anti-fibrotic effect by pericytes in hypoxia. We further proposed a
fibrolytic role of pericyte-derived matrix metalloproteinases (MMPs) and examined gene
expression of MMP-2 and MMP-9 by real-time qPCR. Cultured pericytes expressed more
MMP-2 but nearly 10 times less MMP-9 than total skeletal muscle lysates (tissue origin
control) (Figure 2E). We then explored MMP expression in hypoxia-cultured pericytes and
demonstrated that MMP-2 expression in pericytes was well sustained under 2.5% oxygen,
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compared to normoxic culture (Figure 2F, p>0.05), while MMP-9 expression remained
extremely low without significant change (Figure 2F, p>0.05). Immunohistochemical study
revealed that some of the transplanted pericytes within the infarct region expressed MMP-2
(Figure 2G, a–d).
Transplantation of Pericytes Inhibits Chronic Inflammation
Histological analysis of pericyte- and PBS-injected hearts after hematoxylin and eosin
(H&E) staining indicated an increased focal infiltration of inflammatory cells (cluster of
cells with dark blue-stained nuclei) within the infarct region in the latter (Figure 3A). To
more precisely evaluate the immunomodulatory effect of pericyte transplantation, we
detected host CD68-positive monocytes/macrophages by immunohistochemistry. Pericyte-
injected hearts exhibited diminished infiltration of host phagocytic cells within the infarct
region at 2 weeks post-infarction (Figure 3B). Districts of the myocardium unaffected by the
ischemic insult (posterior and septal walls) contained few CD68-positive cells in either
group, similar to healthy hearts (Figure 3C). Quantitatively, injection of pericytes (N=5)
resulted in a 34% reduction in infiltration of CD68-positive cells at 2 weeks post-infarction
when compared to PBS controls (N=5) (Figure 3D, p<0.001).
Paracrine Immunomodulation by Pericytes
To understand the underlying mechanism of pericyte-induced inhibition of phagocytic cell
infiltration, we analyzed the proliferation of murine macrophages cultured with pericyte-
conditioned medium. Murine macrophage proliferation was significantly inhibited when
culturing with both normoxic (p=0.018) and hypoxic (p<0.001) pericyte-conditioned media,
compared to control medium (Figure 3E). Furthermore, hypoxic pericyte-conditioned
medium exhibited a more prominent immunomodulatory effect than the normoxic
counterpart (Figure 3E, p=0.002). We then investigated by sqRT-PCR the differential
expression of genes encoding immunoregulatory molecules that are potentially accountable
for this paracrine immunomodulation by pericytes. Under either normoxia or hypoxia,
pericytes indeed expressed a considerable array of anti-inflammatory cytokines:
interleukin-6 (IL-6), leukemia inhibitory factor (LIF), cyclooxygenase-2 (COX-2/PTGS-2,
prostaglandin endoperoxide synthase-2) and heme oxygenase-1 (HMOX-1) (Figure 3F).
Similarly, monocyte chemotactic protein-1 (MCP-1) and hypoxia-inducible factor-1α
(HIF-1α) were highly expressed by pericytes (Figure 3F). Conversely, we detected very low
to no expression of pro-inflammatory cytokines including interleukin-1α (IL-1α), tumor
necrosis factor-α (TNF-α), and interferon-γ (IFNγ) (Figure 3F). No expression of
interleukin-4 (IL-4), interleukin-10 (IL-10), inducible nitric oxide synthase (iNOS), and
indoleamine 2,3-dioxygenase (2,3-IDO) was observed (Figure 3F). Quantitatively, there was
no significant alteration of expression under hypoxia of immunoregulatory genes
investigated, except MCP-1, whose expression was notably decreased in hypoxia-cultured
pericytes (Figure 3G, all p>0.05; MCP-1, p=0.027).
Transplanted Pericytes Promote Host Angiogenesis
We examined whether intramyocardial transplantation of pericytes restores the host vascular
network post-infarction. Capillaries in the peri-infarct areas (Figure 4A) and within the
infarct region (Figure 4B) were revealed by anti-mouse CD31 (platelet endothelial cell
adhesion molecule, PECAM-1) immunofluorescent staining and subsequently quantified.
Capillary structure density in the peri-infarct areas of pericyte-injected hearts (N=5) was
increased by 45.4% when compared to PBS-injected controls (N=5) (Figure 4C, p=0.01).
Higher microvascular density was also observed within the infarct region, with 34.8% more
capillaries in the pericyte-treated hearts (Figure 4C, p=0.002). Detection of the proliferating
host ECs by Ki-67, a cell proliferation marker, and CD31 showed that pericyte-injected
hearts (N=3) had significantly more proliferating ECs than PBS-injected controls (N=3) in
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both the infarct region (p=0.034) and peri-infarct areas (p=0.025) (Supplemental Figure
S5A–C). These findings suggest that transplanted pericytes promote host angiogenesis not
only in the peri-infarct areas, where blood vessels were generally better preserved after the
ischemic injury, but also within the blood vessel-deprived infarct region.
Pericytes Support Microvascular Structures
To demonstrate that pericytes benefit host vascular networks through their support of
microvascular structures, we developed 2D and 3D Matrigel cultures/co-cultures using
pericytes and HUVECs. HUVECs seeded onto Matrigel-coated wells formed typical
capillary-like networks after 24 hours (Figure 5A). Pericytes, however, formed similar
structures within 6–12 hours of seeding (Figure 5B). To illustrate the reciprocal influence
between pericytes and endothelial cells (ECs), dye-labeled pericytes (PKH67, green) and
HUVECs (PKH26, red) were mixed and co-cultured in 2D Matrigel, which resulted in the
formation within 6–12 hours of capillary-like structures that included both cell types (Figure
5C). Pericytes (green) were observed to collocate with HUVECs (red) in the co-formed
three-dimensional structures after incubation for 24 hours (Figure 5C, inset). Additionally,
HUVECs (red) appeared to morphologically align with pericytes (green) (Figure 5D). To
further unveil the vascular supportive role of pericytes, an in vitro 3D Matrigel system
designed to simulate native capillary formation was used. HUVECs evenly distributed
within the 3D Matrigel plug were unable to form organized structures after 72 hours (Figure
5E). To the contrary, pericytes started to form capillary-like networks 24 hours after gel-
casting, with structural remodeling over time (Figure 5F). The dynamic interaction between
pericytes and ECs was best depicted by encapsulating dye-labeled pericytes (green) and
HUVECs (red) in a 3D Matrigel plug. Together these two types of cells formed capillary-
like structures after incubation for 72 hours (Figure 5G) with pericytes surrounding
HUVECs (Figure 5H). These data suggest that pericytes retained vascular cell features and
formed structures supportive of microvascular networks even after purification and long-
term culture, while pericyte-EC association may play a role in the pericyte-facilitated
angiogenic process.
Differential Expression of Pro-angiogenic Factors and Associated Receptors by Pericytes
under Hypoxia
The paracrine angiogenic potential of pericytes in the ischemic heart was investigated using
the simulated hypoxic environment in vitro. Expression of genes encoding pro-angiogenic
factors and corresponding receptors was assessed by real-time qPCR. Vascular endothelial
growth factor-A (VEGF-A), platelet-derived growth factor-β (PDGF-β), and transforming
growth factor (TGF)-β1 were notably up-regulated by 307% (p≤0.001), 437% (p=0.067),
and 178% (p=0.037) respectively in pericytes cultured under hypoxic conditions (Figure
6A). Expression of other pro-angiogenic factors, including basic fibroblast growth factor
(bFGF), hepatocyte growth factor (HGF), and epidermal growth factor (EGF), was down-
regulated to 44% (p<0.05), 23% (p≤0.001), and 60% (p>0.05) of their expression levels in
normoxia (Figure 6A). On the other hand, VEGF receptor-1 (VEGFR-1/Flt-1) and -2
(VEGFR-2/KDR/Flk-1) were substantially up-regulated by 458% (p=0.004) and 572%
(p≤0.001) respectively under 2.5% oxygen (Figure 6B). PDGF receptor-β (PDGF-Rβ)
expression was not significantly changed (161%, p>0.05) (Figure 6B). VEGF secretion by
pericytes, measured by ELISA, significantly increased over 3-fold (p≤0.001) under hypoxic
culture conditions while angiopoietin-1 (Ang-1) secretion reduced by 35% (p>0.05) (Figure
6C). Very little secretion of angiopoietin-2 (Ang-2) by pericytes was detected under both
conditions (p>0.05) (Figure 6C). Additionally, TGF-β1 secretion increased by 30.1% under
hypoxia (p=0.028) (Figure 6C), consistent with its up-regulated gene expression. The
expression of human VEGF165 by engrafted pericytes within the infarct region was
confirmed by immunohistochemistry (Figure 6D, a–c).
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Transplanted Pericytes Home to Perivascular Locations
It is not known whether purified pericytes home back to perivascular areas in vivo. To
reveal their engraftment and homing pattern, cultured pericytes were transduced with a GFP
reporter gene at near 95% efficiency (Figure 7A) and injected (3.0×105 cells) into acutely
infarcted hearts. GFP-labeled pericytes engrafted throughout the ventricular myocardium
(Figure 7B), particularly in the peri-infarct area (Supplemental Figure S6). Many donor
pericytes retained expression of NG2, a pericyte marker (Supplemental Figure S7). Confocal
microscopy showed that a fraction of pericytes were identified in perivascular positions,
adjacent to host CD31-positive endothelial cells (Figure 7C). Indeed, pericytes were aligned
with (Figure 7C, main) or surrounding (Figure 7C, inset) CD31-positive microvessels,
suggestive of perivascular homing. The number of engrafted GFP-positive pericytes was
approximately 9.1±1.3% of total injected cells at the first week and declined over time to
3.4±0.5% at 8 weeks post-infarction (N=3 per time point) (Figure 7D, dash-dot line). The
perivascular homing rate instead increased from 28.6% to 40.1% over the course of 8 weeks,
implicating the merit of niche-homing for long-term donor cell survival (Figure 7D, solid
line). To demonstrate cellular interactions between donor pericytes and host ECs, we
performed immunohistochemical studies for ephrin type-B receptor 2 (EphB2) and
connexin43, a gap junction protein. Confocal images revealed that some GFP-positive
pericytes juxtaposing host ECs expressed human-specific EphB2 (Figure 7E) or formed gap
junctions with ECs (Figure 7F). These results suggest cellular interactions between host ECs
and donor pericytes homed to perivascular locations.
Cell Lineage Fate of Transplanted Pericytes
GFP-labeled pericytes were employed to track cell lineages developed from donor pericytes
and investigate the capacity of human muscle pericytes to reconstitute major cardiac cell
types after injury. Immunohistochemistry was performed to simultaneously detect GFP and
cell lineage markers: the cardiomyocyte marker, cardiac troponin-I (cTn-I); the smooth
muscle cell (SMC) marker, smooth muscle myosin heavy chain (SM-MHC); the endothelial
cell (EC) marker, CD31. Confocal microscopy revealed that in the peri-infarct area, a minor
fraction of transplanted pericytes co-express GFP and cTn-I (Supplemental Figure S8A–C,
main), a few of which appear single-nucleated (Supplemental Figure S8A–C, inset). Some
GFP-positive cardiomyocytes were identified within the remaining myocardium
(Supplemental Figure S8D–F) with organized sarcomeric patterns (Supplemental Figure
S8G–I). A very small number of donor pericytes co-expressed GFP and human-specific
CD31 (<1%) (Supplemental Figure S8J-L). Similarly, co-expression of GFP and human-
specific SM-MHC was detected in very few transplanted cells (<0.5%) (Supplemental
Figure S8M–O). Negative control images were stained only with matching fluorescence-
conjugated secondary antibodies (Supplemental Figure S8P–R).
Discussion
Pericytes constitute a major structural component of small blood vessels, regulating vascular
development, integrity and physiology. The recent identification of microvascular pericytes
as one of the native sources of MSC ancestors raised the possibility that these cells
participate in the repair of injured/ageing organs [11–16,35]. The therapeutic potential of
microvascular pericytes was indicated by structural and functional regeneration of skeletal
muscle involving direct pericyte differentiation into regenerative units as well as
applications in lung repair and vascular tissue engineering [8,11,12,35,36]. Pericytes can
also repair tissue via secretion of trophic factors, implying broad usage in clinical settings
[8,18].
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Recent studies indicated a possible developmental hierarchy among different stem/
progenitor cell populations residing in the blood vessel walls [15,37]. Katare et al. reported
that transplantation of adventitial progenitor cells repairs infarcted hearts through
angiogenesis involving microRNA-132 [38]. Herein we demonstrate that transplantation of
human FACS-purified microvascular pericytes contributes to the functional and structural
repair of the ischemic heart, albeit unequally, through both paracrine effects and cellular
interactions. A major goal of SCT, the prevention of progressive LV dilatation and
consequent heart failure, was largely achieved by pericyte treatment, implicating the
attenuation of deleterious remodeling. We also observed significant improvement of cardiac
contractility in an acute infarction milieu, with up to 70% of healthy contractile function
consistently maintained for at least two months. No significant difference was observed
between adult and fetal pericytes in terms of heart repair. The therapeutic benefits observed
could be explained, at least in part, by anti-fibrotic, anti-inflammatory, angiogenic, and to a
lesser extent, cardiomyogenic properties of pericytes.
The anti-fibrotic action of mesodermal stem/progenitor cells in the injured heart has been
reported [25–27]. MSC-conditioned medium diminished viability, proliferation, collagen
synthesis, and α-SMA expression in cardiac fibroblasts but stimulated MMP2/9 activities,
indicating a paracrine anti-fibrotic property of MSCs [26,27]. Our results demonstrated a
near 50% reduction of myocardial fibrosis following pericyte injection. Along with the
attenuation of progressive LV dilatation, pericyte treatment appears to result in propitious
remodeling, leading to improved myocardial compliance and strengthening of the ischemic
cardiac tissue.
We speculated that decreased fibrosis/scar formation is, at least partially, associated with a
reduced number of fibrotic cells resulting from the administration of pericytes. Interestingly,
pericyte-treated hearts contained significantly less cells within the infarct area than PBS-
injected controls (p<0.05, Supplemental Figure S9A) with no statistical difference in
Ki-67(+) proliferating cell density (p=0.808, Supplemental Figure S9B). Additionally,
TUNEL staining revealed no significant difference between pericyte- and PBS-injected
hearts in the number of apoptotic cells within the infarct region (p=0.296, Supplemental
Figure S10A–B). Due to the highly fibrotic nature of MI, we were unable to quantitate
fibrotic cells in vivo. Nevertheless, murine fibroblast proliferation was notably inhibited
when cultured in hypoxic pericyte-conditioned medium in vitro, indicating the paracrine
fibrosuppressive effect of pericytes under hypoxia. MMPs were suggested to play important
roles in post-injury scar remodeling, angiogenesis, and vascular cell proliferation/migration
[27,39]. In particular, a preponderant role of MMP-2 in preventing collagen accumulation by
cardiac fibroblasts was proposed [27]. Consequently, we postulated the existence of a
fibrolytic activity from donor pericytes, involving MMPs, which contributes to the
attenuation of cardiac fibrosis. Indeed, high expression of MMP-2, but not MMP-9, by
pericytes, even under hypoxic conditions, was observed. The expression of MMP-2 was
confirmed in some, but not all, transplanted pericytes, implying a minor role of pericyte-
mediated fibrolysis. Overall, our data suggest that the gross amelioration of fibrosis
presumably involves decreased collagen deposition, reduced proliferation of fibroblasts, and
altered remodeling of the extracellular matrix (ECM). Yet whether there exists one or more
determining mechanism(s) remains to be investigated.
The immunosuppressive potential of MSCs, demonstrated by inhibiting T-lymphocyte
proliferation in culture and counteracting graft-versus-host reaction in recipients of
allogeneic blood stem cells, is currently exploited in clinical trials [28,29]. In the cardiac
milieu, MSC transplantation in a rat model of acute myocarditis mitigated the increase in
CD68+ phagocytic cells [40]. In the present study, pericyte treatment significantly
diminished host monocyte/macrophage infiltration in the infarcted myocardium, suggesting
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an anti-inflammatory potential which contributed to the reduction of fibrosis, amelioration
of adverse remodeling, and improvement of cardiac function. Nevertheless, whether
pericytes inhibit the acute-phase inflammation occurring soon after the incidence of MI is
unknown. Inhibition of murine macrophage proliferation in culture by pericyte-conditioned
medium suggests a paracrine mechanism of their immunomodulatory capacity.
The immunosuppressive and anti-inflammatory capacities of MSCs are primarily attributed
to soluble factors/molecules, as IL-6, LIF, and HMOX-1 were shown to exercise beneficial
immunosuppressive effects [28,29]. The attenuation of intense inflammation and mitigation
of multi-organ damage by MSCs during sepsis are dependent on monocyte/macrophage-
derived cytokines and regulated via PGE2 signaling [41]. The immunoregulatory and
cardioprotective functions of these molecules appear to be similar in the cardiac milieu
[22,42]. Our data demonstrate that pericytes express high levels of IL-6, LIF, COX-2,
HMOX-1, and HIF-1α, which are sustained under hypoxic conditions. MCP-1 expression,
however, notably decreased under hypoxia, corresponding with the reduced CD68+ cell
infiltration in vivo. Little to no expression of pro-inflammatory cytokines including IL-1α,
TNF-α and IFNγ was detected. Virtually no expression of IL-4, IL-10, iNOS, and 2,3-IDO
was observed in pericytes, suggestive of an immunoregulatory cytokine secretome that is
unique to human microvascular pericytes [29,43]. Intriguingly, TGF-β1, also an anti-
inflammatory yet fibrogenic cytokine, was strongly expressed by pericytes [22,44]. Our data
suggested increased TGF-β1 expression/secretion by pericytes under hypoxic conditions
(Figure 6A and 6C). Given the multiple functions each proposed growth factor/cytokine
possesses, it is likely that a dynamic, interactive, and intricately orchestrated balance of
trophic factors between donor and host cells holds the key to a successful ischemic tissue
remodeling and regeneration.
A linear correlation between secretion of pro-angiogenic factors, angiogenesis and cardiac
restoration was illustrated by blocking the bioactivity of VEGF secreted from transplanted
murine muscle-derived stem cells in a mouse MI model, which not only abolished their
stimulation of neovascularization but in turn negatively influenced LV contractility and
infarct size [45]. Okada et al. further delineated the superior angiogenic properties of human
myoendothelial progenitor cells and increased secretion of VEGF in response to hypoxia
[34]. Given the indigenous vascular association of pericytes, we hypothesized that pericytes
are able to repair the damaged host vasculature. Indeed, upon pericyte treatment, we
observed a significantly larger host microvascular network not only in the peri-infarct
collateral circulation but within the infarct region. Cultured pericytes secrete growth factors/
cytokines/chemokines related to vascular physiology and remodeling [18]; among which,
only VEGF-A, PDGF-β, and TGF-β1 were substantially up-regulated under hypoxia,
suggesting their role in pericyte-enhanced angiogenesis [39,46].
Angiogenesis may follow cell-cell contact between donor pericytes and host ECs, in
addition to stimulation by angiogenic factors. Recent studies reported that MSCs and
vascular mural/adventitial cells support ECs in small blood vessel formation and maturation
in culture and in vivo [33,47]. We did observe the perivascular homing of donor pericytes in
the ischemic heart. Some donor pericytes juxtaposing host ECs expressed interactive
molecules including EphB2 and connexin43, suggestive of cellular interactions [48,49].
Planar Matrigel culture confirmed the vascular cell characteristics of pericytes and their
capability to enhance the angiogenic behavior of ECs. We further demonstrated microvessel
formation and vascular support by pericytes in three-dimensional cultures, indicating that
associations between pericytes and ECs may contribute to revascularization. Nevertheless,
the vibrant angiogenic response of pericytes observed in vitro may be reduced in vivo
because of the harsh microenvironment caused by post-MI ischemia and inflammation.
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Altogether, these results demonstrate that the angiogenic properties of pericytes may result
from indirect paracrine effects and, albeit minor, direct cellular interactions.
Compared to other types of stem/progenitor cells, pericytes appear to engraft well in the
infarcted heart initially, presumably attributable to several factors [50]. We did not observe
apparent cell death of pericytes cultured under 2.5% O2 for up to 48 hours, implying their
resistance to hypoxia (data not shown). The increased proliferation and migration of
pericytes in response to low oxygen concentration and ECM degradation products have
important implications for ischemic injury repair [10]. The perivascular niche-homing
capacity may further benefit the long-term survival of pericytes. Nonetheless, it remains
unclear whether pericytes actively migrated to perivascular locations or served as a re-
vascularizing center inducing/recruiting angiogenic proliferation/migration of host ECs.
Future studies are needed to reveal the kinetics of pericyte-EC interaction and migration in
vivo.
The potential of human muscle pericytes to reconstitute major cell types in the injured
myocardium, though to a small extent, was hereby demonstrated. Cell fate tracking suggests
that a minor fraction of donor pericytes differentiated into and/or fused with
cardiomyocytes. Given the small number of GFP-cTnI dual-positive cells present, it is
unlikely that these cells contributed significantly to functional recovery [21]. Pericytes, all
of which were α-SMA-positive during culture expansion, lost α-SMA expression once
homing to host microvasculature (data not shown), consistent with our finding that a subset
of native microvascular pericytes do not express α-SMA in situ [12].
In summary, FACS-purified human microvascular pericytes contribute to anatomic and
functional cardiac improvement post-infarction through multiple cardioprotective
mechanisms: reverse of ventricular remodeling, reduction of cardiac fibrosis, diminution of
chronic inflammation, and promotion of host angiogenesis. Vessel-homing and small-scale
regenerative events by pericytes partially reconstitute lost cardiac cells and contribute to the
structural recovery. These cardioprotective and cardioregenerative activities of a novel stem
cell population that can be purified to homogeneity and expanded in vitro await further
research and exploitation in ischemic cardiovascular diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors wish to thank Alison Logar for excellent technical assistance with flow cytometry, Dr. Bin Sun for
expert assistance in real-time qPCR, Dr. Simon Watkins for confocal microscopy, Dr. Bing Wang for lentiviral-
GFP vectors, James H. Cummins for editorial assistance, as well as Bolat Sultankulov and Damel Mektepbaeva for
insightful discussion. This work was supported by grants from the Commonwealth of Pennsylvania (B.P.), National
Institute of Health R01AR49684 (J.H.) and R21HL083057 (B.P.), the Henry J. Mankin Endowed Chair (J.H.), the
William F. and Jean W. Donaldson Endowed Chair (J.H.), and the Ministry of Education and Science of the
Republic of Kazakhstan (A.S.). C.W.C. was supported in part by the American Heart Association predoctoral
fellowship. M. Corselli was supported by the California Institute for Regenerative Medicine training grant
(TG2-01169).
References
1. American Heart Association. Heart Disease and Stroke Statistics--2011 Update: A Report From the
American Heart Association. Circulation. Feb 1; 2011 123(4):e18–209. [PubMed: 21160056]
2. Kumar, V.; Fausto, N.; Abbas, A. Robbins & Cotran Pathologic Basis of Disease. 7. Philadelphia,
PA: Saunders; 2004.
Chen et al. Page 12
Stem Cells. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Hansson EM, Lindsay ME, Chien KR. Regeneration Next: Toward Heart Stem Cell Therapeutics.
Cell Stem Cell. 2009; 5(4):364–377. [PubMed: 19796617]
4. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008; 451(7181):937–942.
[PubMed: 18288183]
5. Janssens S. Stem Cells in the Treatment of Heart Disease. Annual Review of Medicine. 2010; 61(1):
287–300.
6. Menasche P. Cardiac cell therapy: Lessons from clinical trials. Journal of Molecular and Cellular
Cardiology. 2011; 50(2):258–265. [PubMed: 20600097]
7. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005; 97(6):
512–523. [PubMed: 16166562]
8. Montemurro T, Andriolo G, Montelatici E, et al. Differentiation and migration properties of human
foetal umbilical cord perivascular cells: potential for lung repair. Journal of Cellular and Molecular
Medicine. 2011; 15(4):796–808. [PubMed: 20219017]
9. Park TS, Gavina M, Chen C-W, et al. Placental Perivascular Cells for Human Muscle Regeneration.
Stem Cells and Development. 2011; 20(3):451–463. [PubMed: 20923371]
10. Tottey S, Corselli M, Jeffries EM, Londono R, Peault B, Badylak SF. Extracellular Matrix
Degradation Products and Low-Oxygen Conditions Enhance the Regenerative Potential of
Perivascular Stem Cells. Tissue Engineering Part A. 2011; 17(1–2):37–44. [PubMed: 20653348]
11. Dellavalle A, Sampaolesi M, Tonlorenzi R, et al. Pericytes of human skeletal muscle are myogenic
precursors distinct from satellite cells. Nat Cell Biol. 2007; 9(3):255–267. [PubMed: 17293855]
12. Crisan M, Yap S, Casteilla L, et al. A Perivascular Origin for Mesenchymal Stem Cells in Multiple
Human Organs. Cell Stem Cell. 2008; 3(3):301–313. [PubMed: 18786417]
13. Sacchetti B, Funari A, Michienzi S, et al. Self-Renewing Osteoprogenitors in Bone Marrow
Sinusoids Can Organize a Hematopoietic Microenvironment. Cell. 2007; 131(2):324–336.
[PubMed: 17956733]
14. Feng J, Mantesso A, De Bari C, Nishiyama A, Sharpe PT. Dual origin of mesenchymal stem cells
contributing to organ growth and repair. Proceedings of the National Academy of Sciences. Apr
19; 2011 108(16):6503–6508.
15. Corselli M, Chen C-W, Sun B, Yap S, Rubin PJ, Peault B. The tunica adventitia of human arteries
and veins as a source of mesenchymal stem cells. Stem Cells and Development. 2011; 21(8):1299–
1308. [PubMed: 21861688]
16. Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow
stem cells is correlated with in situ localization. Blood. May 12; 2011 117(19):5067–5077.
[PubMed: 21415267]
17. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B. Perivascular ancestors of adult multipotent
stem cells. Arterioscler Thromb Vasc Biol. Jun; 2010 30(6):1104–1109. [PubMed: 20453168]
18. Chen CW, Montelatici E, Crisan M, Corselli M, Huard J, Lazzari L, Péault B. Perivascular multi-
lineage progenitor cells in human organs: regenerative units, cytokine sources or both? Cytokine
Growth Factor Rev. 2009; 20(5–6):429–434. [PubMed: 19926515]
19. James A, Zara J, Zhang X, et al. Perivascular Stem Cells: A Prospectively Purified Mesenchymal
Stem Cell Population for Bone Tissue Engineering. Stem Cells. 2012 In press.
20. Chen CW, Okada M, Tobita K, Peault B, Huard J. Purified Human Muscle-derived Pericytes
Support Formation of Vascular Structures and Promote Angiogenesis After Myocardial Infarction.
Circulation. 2009; 120:S1053.
21. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine Mechanisms in Adult Stem Cell Signaling and
Therapy. Circ Res. Nov 21; 2008 103(11):1204–1219. [PubMed: 19028920]
22. Frangogiannis NG. The immune system and cardiac repair. Pharmacological Research. 2008;
58(2):88–111. [PubMed: 18620057]
23. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. Journal of Cellular
Biochemistry. 2006; 98(5):1076–1084. [PubMed: 16619257]
24. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction
improves myocardial compliance. Am J Physiol Heart Circ Physiol. Jun 1; 2006 290(6):H2196–
2203. [PubMed: 16473959]
Chen et al. Page 13
Stem Cells. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
25. Pittenger MF, Martin BJ. Mesenchymal Stem Cells and Their Potential as Cardiac Therapeutics.
Circ Res. Jul 9; 2004 95(1):9–20. [PubMed: 15242981]
26. Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N. Mesenchymal stem cells attenuate cardiac
fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Letters. 2007;
581(21):3961–3966. [PubMed: 17662720]
27. Mias C, Lairez O, Trouche E, et al. Mesenchymal stem cells promote matrix metalloproteinase
secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction.
Stem Cells. Nov; 2009 27(11):2734–2743. [PubMed: 19591227]
28. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem
cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010; 1(1):2. [PubMed:
20504283]
29. Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: a new strategy for immunosuppression and
tissue repair. Cell Res. May; 2010 20(5):510–518. [PubMed: 20368733]
30. Renault MA, Losordo DW. Therapeutic myocardial angiogenesis. Microvasc Res. 2007; 74(2–3):
159–171. [PubMed: 17950369]
31. Sieveking DP, Ng MKC. Cell therapies for therapeutic angiogenesis: back to the bench. Vasc Med.
2009; 14(2):153–166. [PubMed: 19366823]
32. Saunders WB, Bohnsack BL, Faske JB, et al. Coregulation of vascular tube stabilization by
endothelial cell TIMP-2 and pericyte TIMP-3. The Journal of Cell Biology. Oct 9; 2006 175(1):
179–191. [PubMed: 17030988]
33. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate
engineering of long-lasting functional vasculature. Blood. 2008; 111(9):4551–4558. [PubMed:
18256324]
34. Okada M, Payne TR, Zheng B, et al. Myogenic Endothelial Cells Purified From Human Skeletal
Muscle Improve Cardiac Function After Transplantation Into Infarcted Myocardium. Journal of
the American College of Cardiology. 2008; 52(23):1869–1880. [PubMed: 19038685]
35. Dellavalle A, Maroli G, Covarello D, et al. Pericytes resident in postnatal skeletal muscle
differentiate into muscle fibres and generate satellite cells. Nat Commun. 2011; 2:499. [PubMed:
21988915]
36. He W, Nieponice A, Soletti L, et al. Pericyte-based human tissue engineered vascular grafts.
Biomaterials. 2010; 31(32):8235–8244. [PubMed: 20684982]
37. Zimmerlin L, Donnenberg VS, Pfeifer ME, et al. Stromal vascular progenitors in adult human
adipose tissue. Cytometry A. Jan; 2010 77(1):22–30. [PubMed: 19852056]
38. Katare R, Riu F, Mitchell K, et al. Transplantation of Human Pericyte Progenitor Cells Improves
the Repair of Infarcted Heart Through Activation of an Angiogenic Program Involving Micro-
RNA-132/Novelty and Significance. Circulation Research. Sep 30; 2011 109(8):894–906.
[PubMed: 21868695]
39. Enciso JM, Hirschi KK. Understanding Abnormalities in Vascular Specification and Remodeling.
Pediatrics. Jul 1; 2005 116(1):228–230. [PubMed: 15995057]
40. Ohnishi S, Yanagawa B, Tanaka K, et al. Transplantation of mesenchymal stem cells attenuates
myocardial injury and dysfunction in a rat model of acute myocarditis. Journal of Molecular and
Cellular Cardiology. 2007; 42(1):88–97. [PubMed: 17101147]
41. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via
prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10
production. Nat Med. Jan; 2009 15(1):42–49. [PubMed: 19098906]
42. Liu X, Pachori AS, Ward CA, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct
remodeling and restores ventricular function. Faseb J. Feb; 2006 20(2):207–216. [PubMed:
16449792]
43. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-
mediated immunosuppression. Stem Cells. Aug; 2009 27(8):1954–1962. [PubMed: 19544427]
44. Abarbanell AM, Coffey AC, Fehrenbacher JW, et al. Proinflammatory cytokine effects on
mesenchymal stem cell therapy for the ischemic heart. Ann Thorac Surg. Sep; 2009 88(3):1036–
1043. [PubMed: 19699961]
Chen et al. Page 14
Stem Cells. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
45. Payne TR, Oshima H, Okada M, Momoi N, Tobita K, Keller BB, Peng H, Huard J. A relationship
between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell
transplantation into ischemic hearts. J Am Coll Cardiol. 2007; 50(17):1677–1684. [PubMed:
17950150]
46. Ohnishi S, Yasuda T, Kitamura S, Nagaya N. Effect of Hypoxia on Gene Expression of Bone
Marrow-Derived Mesenchymal Stem Cells and Mononuclear Cells. Stem Cells. 2007; 25(5):1166–
1177. [PubMed: 17289933]
47. Campagnolo P, Cesselli D, Al Haj Zen A, et al. Human Adult Vena Saphena Contains Perivascular
Progenitor Cells Endowed With Clonogenic and Proangiogenic Potential. Circulation. Apr 20;
2010 121(15):1735–1745. [PubMed: 20368523]
48. Salvucci O, de la Luz Sierra M, Martina JA, McCormick PJ, Tosato G. EphB2 and EphB4
receptors forward signaling promotes SDF-1–induced endothelial cell chemotaxis and branching
remodeling. Blood. Nov 1; 2006 108(9):2914–2922. [PubMed: 16840724]
49. Hirschi KK, Burt JM, Hirschi KD, Dai C. Gap Junction Communication Mediates Transforming
Growth Factor-β Activation and Endothelial-Induced Mural Cell Differentiation. Circulation
Research. Sep 5; 2003 93(5):429–437. [PubMed: 12919949]
50. Wu KH, Mo XM, Han ZC, Zhou B. Stem Cell Engraftment and Survival in the Ischemic Heart.
The Annals of Thoracic Surgery. 2011; 92(5):1917–1925. [PubMed: 21955573]
Chen et al. Page 15
Stem Cells. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Survival rate and cardiac functional assessment
(A) Cumulative survival rate of the animals over 8 weeks post-surgery (Kaplan-Meier
Survival Curve, log-rank test p=0.529). Echocardiographic analyses revealed a significant
reduction of LV dilatation by transplantation of all three pericyte populations (AP, FP1, and
FP2), as shown by the smaller LV area in end-diastole (B) and end-systole (C) of hearts at
both time points. Injection of pericytes also resulted in substantial improvement in LV
contractility, as indicated by greater fractional shortening (D), fractional area change (E),
and ejection fraction (F), at both time points.
(†p≤0.001; §p≤0.005; #p≤0.01; *p≤0.05; versus PBS control group at each time point)
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Figure 2. Attenuation of myocardial fibrosis by pericyte treatment
(A) Masson’s trichrome-stained transverse sections of hearts injected with pericytes or PBS
(collagen in blue/purple, cardiac muscle in red; scale bars=1 mm). (B) The fibrotic area
fraction was dramatically decreased in pericyte-injected hearts (p≤0.001). (C) Pericyte group
had no significant increase in the infarct wall thickness. (D) When culturing with hypoxic
pericyte-conditioned medium (P-CM), the proliferation of murine cardiac fibroblasts was
significantly reduced (†p=0.019, versus normoxic P-CM) while muscle fibroblast
proliferation exhibited the same pattern (*p<0.001). Normoxic P-CM had a pro-proliferative
effect over control medium in muscle fibroblasts, but not in cardiac fibroblasts (#p<0.05).
Skeletal myoblast proliferation was not significantly affected by either of the P-CMs. (E)
Expression of MMP-2 in cultured pericytes was higher than that in skeletal muscle lysates.
Conversely, MMP-9 expression in pericytes was nearly 10 times less (logarithmic scale of
10 in arbitrary fluorescence units). (F) Expression of both MMP-2 and -9 in pericytes did
not change significantly under hypoxia (p>0.05, logarithmic scale of 10 in arbitrary
fluorescence units). (G) Immunohistochemistry revealed MMP-2 expression (red arrows) by
some of the GFP-labeled donor pericytes (green arrows) within the infarct area at 2 weeks
post-infarction (a) merge (b) anti-GFP in green (c) MMP-2in red (d) DAPI nuclei staining in
blue (scale bar=20μm).
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Figure 3. Reduction of host phagocytic cell infiltration by pericyte transplantation
(A) H&E staining revealed a greater focal infiltration of leukocytes (dark blue-stained
nuclei) within the infarct region in PBS-injected controls at 2 weeks post-infarction (scale
bars=100μm). (B) Anti-mouse CD68 immunostaining showed that the infarct region of
pericyte-injected hearts contains less host phagocytic cells (scale bars=50μm). (C) Host
CD68-positive cells were locally attracted to the infarct region but not to the unaffected
myocardium (posterior ventricular wall) in both groups (scale bars=50μm). (D) Host
monocytes/macrophage infiltration at the infarct site was significantly reduced (p<0.001).
(E) The proliferation of murine macrophages was significantly inhibited when culturing with
pericyte-conditioned media (*p=0.018, #p<0.001, versus control medium), an effect more
prominent with hypoxic pericyte-conditioned medium (†p=0.002, hypoxia versus normoxia).
(F) Cultured pericytes exhibited sustained, high expression of genes regulating the
inflammatory responses, even under 2.5% O2 (N: normoxia; H: hypoxia). Little expression
of IL-1α and no expression of IL-4, IL-10, iNOS, 2,3-IDO, TNF-α, and IFNγ were
detected. (G) No statistically significant difference in expression of genes of
immunoregulatory molecules between normoxic- and hypoxic-cultured pericytes except
MCP-1, which notably decreased in hypoxic cultures (sqRT-PCR analysis, p=0.027).
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Figure 4. Promotion of host angiogenesis by pericyte treatment
Representative images of anti-mouse CD31 immunostaining (A) in the peri-infarct area and
(B) within the infarct region of hearts injected with pericytes or PBS (scale bars=50μm). (C)
Pericyte-treated hearts displayed significantly higher capillary densities in the peri-infarct
area (p<0.05) and within the infarct region (p<0.001).
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Figure 5. Pericytes support microvascular structures
(A) While HUVECs seeded onto Matrigel-coated wells formed typical capillary-like
networks after 24 hours, (B) pericytes formed similar structures within 6–12 hours (scale
bars=1mm). (C) When co-cultured on Matrigel, dye-labeled pericytes (green) and HUVECs
(red) co-formed capillary-like networks within 6–12 hours, ([C], inset) with collocations of
pericytes and HUVECs in three-dimensional structures formed 24 hours after seeding (scale
bars: main=200μm; inset=100μm). (D) HUVECs (red) appear to line and spread out on top
of the pericyte-formed structures (green) (scale bar=100μm). (E) To simulate native
capillary formation, HUVECs were evenly encapsulated into 3D Matrigel plug for 72 hours
but unable to form any organized structure (scale bars=1mm). (F) Pericytes instead formed
capillary-like networks in Matrigel plug with structural organization and maturation over
time (scale bars=1mm). (G) When dye-labeled pericytes (green) and HUVECs (red) were
co-casted into the 3D-gel plug, the two types of cells formed microvessel-like networks
within 72 hours, (H) with pericytes surrounding HUVECs (scale bars: G=200μm;
H=50μm).
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Figure 6. Expression of pro-angiogenic factors and associated receptors under hypoxia
(A) Pericytes dramatically up-regulated VEGF-A, PDGF-β, TGF-β1 gene expression under
hypoxic conditions (2.5% O2) while expression of other pro-angiogenic factors, including
bFGF, HGF and EGF were distinctively repressed. (B) Simultaneously, VEGFR-1 (Flt-1)
and -2 (Flk-1) were substantially up-regulated, and PDGF-Rβ expression was moderately
increased. All expression levels are normalized to human cyclophilin and presented in
arbitrary fluorescence units on an expanded logarithmic scale (#p<0.05, *p≤0.001, †p<0.01,
hypoxia versus normoxia). (C) Significantly increased secretion of VEGF (p≤0.001) and
TGF-β1 (p=0.028) by pericytes under hypoxic culture conditions was detected by ELISA
while secretion of Ang-1 was reduced by 35% (p>0.05). Very little secretion of Ang-2 was
detected under both conditions (p>0.05). (D) Immunohistochemistry revealed human
VEGF165 expression by GFP-labeled donor pericytes within the infarct area at 2 weeks post-
infarction (a) merge (b) hVEGF165 in red (c) anti-GFP in green (scale bar=50μm).
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Figure 7. Transplanted pericytes home to perivascular locations
(A) Pericytes were transduced with GFP reporter at nearly 95% efficiency. Fluorescence
([A], main) and bright-field ([A], inset) images were taken from the same low-power field
(scale bars=200μm). (B) Engraftment of GFP-labeled pericytes within host myocardium
was revealed by anti-GFP immunostaining at 1 week post-injection (scale bar=500μm,
infarct site encircled by dotted lines). (C) Pericytes were lining with ([C], main) or
surrounding ([C], inset) host CD31-positive microvasculature (scale bars=20μm). (D) The
engraftment efficiency of pericytes at 1 week (9.1±1.3%) and 8 weeks (3.4±0.5%) post-
infarction was depicted (dash-dot line). The perivascular homing ratio instead increased
from 28.6% to 40.1% and was delineated separately (solid line). Some GFP-positive
pericytes juxtaposing host ECs (E) expressed human-specific EphB2 (green/white arrows)
or (F) formed connexin43-positive gap junctions with ECs (red arrow heads) (scale
bars=10μm).
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